Specialty Pharmacy in a Biosimilar-First World: Workflow, Access, and Adherence
- 0:00 Why Biosimilar-First Changes Everything
- 10:00 Channel Economics And Control Points
- 19:00 Workflow Friction In Practice
Practical shifts you can apply this week
-
Identify Workflow Change Points
Spot where intake, benefits, dispense, and follow-up break when biosimilar-first policies take hold.
-
Evaluate Access Barriers
Assess how formulary design, utilization management, and interchange rules slow starts or create rework.
-
Compare Adherence Risks
See where switching raises drop-off risk across infusion, clinic, and self-administered care settings.
-
Design Pharmacy Interventions
Build steps that protect speed to therapy while supporting conversion and persistence after switching.
-
Draft Cross-Functional Action Plan
Leave with a practical plan for payer, provider, and patient-facing biosimilar implementation.
What we'll cover
-
0:00
Why Biosimilar-First Changes Everything
Why this is more than contracting, and where the specialty pharmacy journey starts to bend.
-
10:00
Channel Economics And Control Points
How payers, PBMs, networks, and buy-and-bill realities shape uptake more than slide decks do.
-
19:00
Workflow Friction In Practice
Real handoff failures: PA loops, NDC and J-code confusion, sourcing issues, and order-entry mismatches.
-
31:00
Access Beyond Formulary Wins
What it takes to make a preferred biosimilar actually feel accessible to providers and patients.
-
41:00
Adherence Risks During Switching
Where trust gaps, device changes, and site-of-care shifts create avoidable discontinuation.
-
51:00
Metrics That Actually Matter
Track time to therapy, first-fill success, reversals, abandonment, and persistence after conversion.
-
56:00
30-Day Playbook And Q&A
Recap the blueprint, choose one therapy area, and leave with a practical first-month next step.
Questions people ask before registering
-
It is built for working professionals across specialty pharmacy, market access, reimbursement, clinical operations, and provider support. If biosimilar policy changes touch your workflow, this will feel familiar in a useful way.
-
No. We assume you know healthcare operations, but not every biosimilar wrinkle. The session starts with the operating model shift, then moves into practical examples.
-
Tactical. You will see workflow points, access barriers, adherence risks, and a 30-day implementation playbook. Think fewer slogans, more handoffs and resubmission loops.
-
If a replay is offered by the host, registered attendees typically receive follow-up details after the event. Live attendance is still the best way to ask questions tied to your setting.
-
Certificate or CE availability depends on the event host and accreditation setup. Check the registration details for the final policy before you sign up.
-
A practical blueprint to redesign workflow, access strategy, and adherence support for biosimilar-first care. You should also have one concrete next step for the next 30 days.